ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
Phacoemulsification combined glaucoma surgeries in the treatment of nanophthalmos patients with secondary angle closure glaucoma.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo evaluate the efficacy and safety of phacoemulsification combined with glaucoma surgeries based on new criteria of axial length (AL) in nanophthalmos patients with secondary angle closure glaucoma (NSACG).
methodsThis retrospective study analyzed medical records of NSACG patients, categorized into two groups based on AL. Group 1 (AL: 17-20 mm) underwent phacoemulsification with intraocular lens implantation, viscogonioplasty, and anterior pars plana vitrectomy (PVP), combined with trabeculectomy (Trab) or endoscopic photocoagulation (ECP). Group 2 (AL < 17 mm) underwent PVP combined with trabeculectomy and sclerectomy (PVPTS).
resultsA total of 22 patients (31 eyes) with NSACG were enrolled with a mean follow-up of 50.2 ± 26.2 months. Patients with axial length < 17 mm (Group 2) exhibited significantly worse visual acuity (P < 0.05) and required more IOP-lowering medications (P = 0.007) than those with axial length ≥ 17 mm (Group 1). Postoperatively, both groups demonstrated statistically significant reductions in IOP and the number of IOP-lowering medications (All P < 0.05). IOP reduction ≥ 20% was achieved in 92.3% (Group 1) and 94.4% (Group 2), with IOP < 21 mmHg in 69.2% and 77.8%, respectively. No postoperative malignant glaucoma occurred in either group.
conclusionsPVP combined with Trab or ECP and PVPTS are effective and safe surgical interventions for patients with NSACG. Surgeries applied using the new criteria of AL have the potential to achieve better IOP control outcomes with lower complication rates. KEY MESSAGES: What was known before Nanophthalmos with secondary angle closure glaucoma (NSACG) is challenging to manage surgically due to unique anatomical features and high risk of complications. Short axial length (AL) is a risk factor for postoperative complications in nanophthalmos. What that study adds Phacoemulsification with viscogonioplasty and anterior pars plana vitrectomy (PVP) combined with trabeculectomy or endoscopic cyclophotocoagulation is effective and safe for NSACG patients with AL ≥ 17 mm and < 20 mm. PVP combined with trabeculectomy and sclerectomy (PVPTS) is effective and safe for NSACG patients with AL < 17 mm. The new AL criteria can be considered an effective surgical intervention strategy in treating patients with NSACG.
Indexed as
Identifiers
39964556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.